Genitourinary Cancer Pain Syndromes

  • Ilan Margulis
  • Amitabh Gulati


Genitourinary and gynecological malignancies include bladder, prostate, renal cell, uterine, ovarian, cervical, and testicular cancers. These all present differently and symptoms vary among patients. It is estimated that at least 70% of patients have pain syndromes associated with their pathology [Office for National Statistics Cancer statistics registrations: registrations of cancer diagnosed in 2002 England, Series MB1 no. 33. Office for National Statistics, London, 2005]. While pain may be the result of the disease process itself, it may also be the consequence of therapies used when treating malignancies. Furthermore, patients may have pain from sites primarily involved or from distant metastases. The following chapter discusses potential pain syndromes a cancer patient may face and how techniques and paradigms in pain management strategies can improve the patient’s pain symptoms.


Genitourinary cancer Superior hypogastric block Ganglion of impar block Prostate cancer Renal cancer Bladder cancer Uterine cancer 


  1. 1.
    Office for National Statistics Cancer statistics registrations: registrations of cancer diagnosed in 2002 England. Series MB1 no. 33. London: Office for National Statistics, 2005.Google Scholar
  2. 2.
    Siegel R, et al. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29.CrossRefGoogle Scholar
  3. 3.
    Ali M, et al. Anatomy of the pelvic plexus and innervation of the prostate gland. Clin Anat. 2004;17(2):123–9.CrossRefGoogle Scholar
  4. 4.
    Eman A, Serbülent G, Gürcü ME. Pain management in prostate cancer. Open J Urol. 2012;2(3):164.CrossRefGoogle Scholar
  5. 5.
    Bader P, et al. Prostate cancer pain management: EAU guidelines on pain management. World J Urol. 2012;30(5):677–86.CrossRefGoogle Scholar
  6. 6.
    Autio KA, et al. Prevalence of pain and analgesic use in men with metastatic prostate cancer using a patient-reported outcome measure. J Oncol Pract. 2013;9(5):223–9.CrossRefGoogle Scholar
  7. 7.
    Khosla A, Adeyefa O, Nasir S. Successful treatment of radiation-induced proctitis pain by blockade of the ganglion impar in an elderly patient with prostate cancer: a case report. Pain Med. 2013;14:662–6. Scholar
  8. 8.
    Gulati A, Khelemsky Y, Loh J, Puttanniah V, Malhotra V, Cubert K. The use of lumbar sympathetic blockade at L4 for management of malignancy-related bladder spasms. Pain Physician. 2011;14(3):305–10.PubMedGoogle Scholar
  9. 9.
    Portenoy RK, et al. Pain in ovarian cancer patients. Prevalence, characteristics, and associated symptoms. Cancer. 1994;74(3):907–15.CrossRefGoogle Scholar
  10. 10.
    Noronha AF, Mello de Figueiredo E, Rossi de Figueiredo Franco TM, Cândido EB, Silva-Filho AL. Treatments for invasive carcinoma of the cervix: what are their impacts on the pelvic floor functions? Int Braz J Urol. 2013;39(1):46–54.CrossRefGoogle Scholar
  11. 11.
    Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001;27(3):165–76.CrossRefGoogle Scholar
  12. 12.
    Serafini AN. Therapy of metastatic bone pain. J Nucl Med. 2001;42(6):895–906.PubMedGoogle Scholar
  13. 13.
    Buga S, Sarria JE. The management of pain in metastatic bone disease. Cancer Control. 2012;19(2):154–66.CrossRefGoogle Scholar
  14. 14.
    Birthi P, Sloan P. Interventional treatment of refractory cancer pain. Cancer J. 2013;19(5):390–6.CrossRefGoogle Scholar
  15. 15.
    Hutson N, Hung JC, Puttanniah V, Lis E, Laufer I, Gulati A. Interventional pain management for sacroiliac tumors in the oncologic population: a case series and paradigm approach. Pain Med. 2017;18(5):959–68.PubMedGoogle Scholar
  16. 16.
    Brejt N, et al. Pelvic radiculopathies, lumbosacral plexopathies, and neuropathies in oncologic disease: a multidisciplinary approach to a diagnostic challenge. Cancer Imaging. 2013;13(4):591.CrossRefGoogle Scholar
  17. 17.
    Amr YM, Makharita MY. Neurolytic sympathectomy in the management of cancer pain – time effect: a prospective, randomized multicenter study. J Pain Symptom Manag. 2014;48(5):944–56.CrossRefGoogle Scholar
  18. 18.
    Woo JH, Park HS, Kim SC, Kim YH. The effect of lumbar sympathetic ganglion block on gynecologic cancer-related lymphedema. Pain Physician. 2013;16(4):345–52.PubMedGoogle Scholar
  19. 19.
    de Oliveira R, dos Reis MP, Prado WA. The effects of early or late neurolytic sympathetic plexus block on the management of abdominal or pelvic cancer pain. Pain. 2004;110(1):400–8.CrossRefGoogle Scholar
  20. 20.
    Ahmed DG, Mohamad MF, Mohamed SA-E. Superior hypogastric plexus combined with ganglion impar neurolytic blocks for pelvic and/or perineal cancer pain relief. Pain Physician. 2015;18(1):E49–56.PubMedGoogle Scholar
  21. 21.
    Stogicza A, et al. Inferior hypogastric plexus block affects sacral nerves and the superior hypogastric plexus. ISRN Anesthesiology. 2012;2012:1–5.CrossRefGoogle Scholar
  22. 22.
    Saito T, Den S, Tanuma K, Tanuma Y, Carney E, Carlsson C. Anatomical bases for paravertebral anesthetic block: fluid communication between the thoracic and lumbar paravertebral regions. Surg Radiol Anat. 1999;21(6):359–63.CrossRefGoogle Scholar
  23. 23.
    Mishra S, Bhatnagar S, Rana SP, Khurana D, Thulkar S. Efficacy of the anterior ultrasound-guided superior hypogastric plexus neurolysis in pelvic cancer pain in advanced gynecological cancer patients. Pain Med. 2013;14(6):837–42.CrossRefGoogle Scholar
  24. 24.
    Eker HE, Cok OY, Kocum A, Acil M, Turkoz A. Transsacrococcygeal approach to ganglion impar for pelvic cancer pain: a report of 3 cases. Reg Anesth Pain Med. 2008;33(4):381–2.PubMedGoogle Scholar
  25. 25.
    Elahi, et al. Pudendal entrapment neuropathy: a rare complication of pelvic radiation therapy. Pain Physician. 2013;16:E793–7.PubMedGoogle Scholar
  26. 26.
    Prologo JD, et al. Percutaneous CT-guided cryoablation for the treatment of refractory pudendal neurologia. Skelet Radiol. 2015;44:709–14.CrossRefGoogle Scholar
  27. 27.
    Candido K, Stevens RA. Intrathecal neurolytic blocks for the relief of cancer pain. Best Pract Res Clin Anaesthesiol. 2003;17(3):407–28. Becker R, Sure U, Bertalanffy H. Punctate midline myelotomy a new approach in the management of visceral pain. Acta Neurochir 1999;141(8): 881–883.Google Scholar
  28. 28.
    Becker R1, Gatscher S, Sure U, Bertalanffy H. The punctate midline myelotomy concept for visceral cancer pain control-case report and review of the literature. Acta Neurochir Suppl. 2002;79:77–8.Google Scholar
  29. 29.
    Nauta HJW, et al. Punctate midline myelotomy for the relief of visceral cancer pain. J Neurosurg Spine. 2000;92(2):125–30.CrossRefGoogle Scholar
  30. 30.
    Flagg II, Artemus, McGreevy K, Williams K. Spinal cord stimulation in the treatment of cancer-related pain:“back to the origins”. Curr Pain Headache Rep. 2012;16(4):343–9.CrossRefGoogle Scholar
  31. 31.
    Cameron T. Safety and efficacy of spinal cord stimulation for the treatment of chronic pain: a 20-year literature review. J Neurosurg Spine. 2004;100(3):254–67.CrossRefGoogle Scholar
  32. 32.
    Baranidharan G, Simpson KH, Dhandapani K. Spinal cord stimulation for visceral pain – a novel approach. Neuromodulation. 2014;17(8):753–8.CrossRefGoogle Scholar
  33. 33.
    Deer TR, et al. Comprehensive consensus based guidelines on intrathecal drug delivery systems in the treatment of pain caused by cancer pain. Pain Physician. 2011;14(3):E283–312.PubMedGoogle Scholar
  34. 34.
    Bruel BM, Burton AW. Intrathecal therapy for cancer-related pain. Pain Med. 2016;17(12):2404–21.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Ilan Margulis
    • 1
  • Amitabh Gulati
    • 2
  1. 1.Department of AnesthesiologyNew York-Presbyterian Hospital/Weill Cornell MedicineNew YorkUSA
  2. 2.Department of Anesthesiology and Critical CareMemorial Sloan Kettering Cancer CenterNew YorkUSA

Personalised recommendations